Filed with ASX · · 5 pages · English
The company reported record trading results and a successful audit by the Therapeutic Goods Administration, which included both its South Granville headquarters and a new facility in Auburn. Additionally, Cryosite has completed an extension of its cool room capacity, which is expected to enhance its service offerings in response to increasing client demand. The outlook remains positive as the company anticipates continued momentum in the clinical trials market and is well-positioned for future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
19 October 2026 Trading and TGA Licensing Update – Q1 FY27 Dear Shareholders, Cryosite Limited (ASX: CTE) is pleased to provide the following update on its unaudited financial and operational performance for the quarter ended 30 September 2026 (Q1 FY27). The quarter delivered record trading...
Follow Cryosite into a list and get an email when it puts out news.
Follow Cryosite